Trials / Completed
CompletedNCT00002106
A Pilot Randomized, Double-Blind, Placebo-Controlled, Parallel Design, Multicenter Trial to Evaluate the Effect of Ranitidine on Immunologic Indicators in Asymptomatic HIV-1 Infected Subjects With a CD4 Cell Count Between 400-700 Cells/mm3
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (planned)
- Sponsor
- Glaxo Wellcome · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect of ranitidine on immunologic indicators in asymptomatic HIV-1 infected patients with CD4 counts of 400-700 cells/mm3.
Detailed description
Patients are randomized to receive either ranitidine or matching placebo bid for 16 weeks, with follow-up every 4 weeks through week 20.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranitidine hydrochloride |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2005-06-24
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00002106. Inclusion in this directory is not an endorsement.